文献速递浆细胞疾病

髓外骨髓瘤具有基因组复杂性且几乎普遍存在MAPK通路改变

Extramedullary myeloma is genomically complex and characterized by near-universal MAPK pathway alterations.
PubMed 文献 · Blood Adv · 2025-01-01

研究对18例患者的髓外病变(EMD)组织和20例患者在EMD发生时的骨髓穿刺液行全外显子测序,其中6例有配对样本。EMD样本MAPK通路突变近乎普遍(94%),高于骨髓(60%;比值比10.7;P=.02;q<0.1),且基因组复杂性显著更高。

要点

  • EMD样本MAPK通路突变见于94%,骨髓样本为60%(比值比10.7;P=.02;q<0.1)
  • NRAS、KRAS和BRAF等驱动基因突变常见且多为克隆性
  • EMD样本肿瘤突变负荷更高且1q获得/扩增富集,基因组复杂性显著高于骨髓

核心结论

  • EMD的分子谱与骨髓穿刺液不同,EMD具有基因组复杂和异质性特征。

研究设计与样本

  • 对18例患者的EMD肿瘤组织和20例患者在EMD发生时的骨髓穿刺液行全外显子测序,其中6例为EMD诊断时采集的配对EMD与骨髓样本。

主要发现

  • EMD样本MAPK通路突变见于94%,骨髓穿刺液样本为60%(比值比10.7;P=.02;q<0.1)。
  • NRAS、KRAS和BRAF等已知驱动基因突变常见且多为克隆性。
  • 检出ROBO1、ROBO2和FAT1等细胞黏附与迁移相关基因以及SWI/SNF复合物和表观遗传调控基因(ARID1A、KMT2C、KMT2D和EP300)的改变,但多为亚克隆性。
  • 常检出肿瘤抑制基因MAX(22%)和CDKN2C(17%)的双等位改变。
  • EMD样本肿瘤突变负荷增高且1q获得/扩增富集,基因组复杂性显著高于骨髓穿刺液样本。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Extramedullary disease (EMD) is associated with an inferior prognosis and lower response rates to conventional multiple myeloma (MM)-directed therapies compared to MM without EMD. A deeper understanding of the molecular landscape and underlying drivers of EMD is essential to identify potential targets for novel therapeutic strategies. To address this, we performed whole-exome sequencing on EMD tumor tissue from 18 unique patients and bone marrow aspirates (BMAs) from 20 patients at the time of EMD development. Notably, paired EMD and BMA samples were collected from 6 patients at the point of EMD diagnosis, allowing for direct comparison of molecular profiles. Our analysis revealed a near-universal presence of mutations within the MAPK pathway in EMD samples (94%), compared to BMAs (60%; odds ratio, 10.7; P = .02; q < 0.1). Additionally, mutations in established driver genes (NRAS, KRAS, and BRAF) were common and frequently clonal, suggesting their central role in EMD pathogenesis. We also identified alterations in genes associated with cell adhesion and migration (ROBO1, ROBO2, and FAT1) and the SWI/SNF complex and epigenetic regulators (ARID1A, KMT2C, KMT2D, and EP300), although these were predominantly subclonal. Furthermore, we frequently detected biallelic alterations in the tumor suppressor genes MAX (22%), a binding partner for MYC, and CDKN2C (17%). Genomic complexity was significantly higher in EMD samples than BMAs, as evidenced by increased tumor mutational burden and the enrichment of 1q gain/amplifications. These findings underscore the distinct molecular profile of EMD compared to BMA and highlight the genomically complex and heterogeneous nature of extramedullary disease in MM.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zanwar S, Novak J, Gonsalves W, et al. Extramedullary myeloma is genomically complex and characterized by near-universal MAPK pathway alterations. Blood Adv. 2025. PMID: 40367415. doi:10.1182/bloodadvances.2025016619

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。